Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
LQWD Technologies Lightning Network Infrastructure Surpasses 1 Million Global Transactions (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Eli Lilly and Co LLY

Healthcare
Eli Lilly and Company is a medicine company. The Company discovers, develops, manufactures and markets products in the human pharmaceutical products segment. Its diabetes, obesity and other cardiometabolic products include Basaglar, Humalog, Mounjaro, Trulicity and Zepbound. Its oncology products include Alimta, Retevmo, Tyvyt and Verzenio. Its immunology products include Ebglyss, Olumiant, Omvoh and Taltz. Its neuroscience products include Cymbalta and Emgality. Its other products and therapies include Cialis and Forteo. It manufactures and distributes its products through facilities in the United States (U.S.), including Puerto Rico, and in Europe and Asia. The Company, through its subsidiary, POINT Biopharma Global Inc., is engaged in radiopharmaceutical discovery, development, and manufacturing, as well as clinical and pre-clinical radioligand therapies. It is also developing oral small molecule inhibitor of a4ß7 integrin (known as MORF-057) for inflammatory bowel disease (IBD).


NYSE:LLY - Post by User

Eli Lilly and Co
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(228)
•••
Post by whytestockson Aug 30, 2024 4:33pm
339 Views
Post# 36203376

Think Eli Lilly Stock Has Peaked? These 10 Words From the CE

Think Eli Lilly Stock Has Peaked? These 10 Words From the CE
News; $LLY Think Eli Lilly Stock Has Peaked? These 10 Words From the CEO May Change Your Mind2024-08-30 07:45:00 ET Eli Lilly (NYSE: LLY) stock is up a mammoth 770% in five years. It is trading at new all-time highs in 2024 thanks to the incredible success and popularity of its diabetes and weight loss products, Mounjaro and Zepbound. But with the stock standing at a market...LLY - Think Eli Lilly Stock Has Peaked? These 10 Words From the CEO May Change Your Mind

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities